TITLE

New checkpoint inhibitors ride the immunotherapy tsunami

AUTHOR(S)
Mullard, Asher
PUB. DATE
July 2013
SOURCE
Nature Reviews Drug Discovery;Jul2013, Vol. 12 Issue 7, p489
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The article reports that a growing number of U.S. pharmaceutical firms are developing drugs that target the programmed cell death protein 1 (PD1) and its ligand PDL1. In June 2013, data from clinical trials of monoclonal antibodies was presented at the American Society of Clinical Oncology (ASCO) meeting. Immunotherapies are expected to generate 35 billion U.S. dollars in sales by 2023, says Citigroup analyst Andrew Baum.
ACCESSION #
88783763

 

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics